The Effect of FGF23 on Cardiac Hypertrophy Is Not Mediated by Systemic Renin-Angiotensin- Aldosterone System in Hemodialysis

The Effect of FGF23 on Cardiac Hypertrophy Is Not Mediated by Systemic Renin-Angiotensin- Aldosterone System in Hemodialysis

Fibroblast growth factor 23 (FGF23) is elevated in patients with chronic kidney disease and contributes to left ventricular hypertrophy (LVH). The aim of the analysis was to determine whether this effect is mediated by the renin-angiotensin-aldosterone system (RAAS) in hemodialysis. Serum samples fr...

Full description

Bibliographic Details
Main Authors: Katharina Dörr, Michael Kammer, Roman Reindl-Schwaighofer, Matthias Lorenz, Rodrig Marculescu, Marko Poglitsch, Dietrich Beitzke, Rainer Oberbauer
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-04-01
Series:Frontiers in Medicine
Subjects:
renin-angiotensin-aldosterone-system
FGF23
hemodialysis
left ventricular hypertrophy
chronic kidney disease
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2022.878730/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2022.878730/full

Similar Items